• Based on the 2026 ASCO Annual Meeting held in Chicago, USA.
A simplified summary for patients from the world's largest cancer congress.
Every year in May–June, cancer specialists from all over the world gather. ASCO Annual Meeting‘They come together in 2026. This meeting is where the most important innovations in cancer treatment are announced for the first time. Over 40,000 experts participated. Below, we have summarized the most noteworthy and promising results for patients in language that can be understood by those without medical training.
Pancreatic Cancer — It almost doubled life expectancy.
Pancreatic cancer is one of the most difficult cancers to treat, and for years there had been no significant progress in this area. Therefore... daraxonrasib The results of a new drug called [drug name] were the most talked-about news at the meeting. This drug targets what causes cancer cells to grow. RAS targeting a protein called, an oral pilltruck.
In the RASolute 302 study, the drug also produced fewer serious side effects compared to chemotherapy.
For this type of cancer, where options have been very limited for many years, a new treatment that offers both longer survival and better quality of life, and can be taken as a pill instead of an injection, is on the horizon. The drug's approval process has begun.
Prostate Cancer — Surgery reduced the risk of spread.
In high-risk but not yet metastatic prostate cancer, patients usually undergo surgery; however, in about half of them, the cancer returns over time. PROTEUS study, hormone therapy before and after surgery apalutamide They examined the results of adding a pill called [name of pill].
In early-stage, high-risk prostate cancer, supplementing surgery with potent medication may delay disease recurrence. This approach is considered to have the potential to change a treatment philosophy that has remained unchanged for decades.
Bowel Cancer · BRAF — Life expectancy has doubled.
In a small percentage of bowel cancers BRAF V600E They have a genetic mutation called [name of mutation], and the course of the disease is generally more difficult for these patients. BREAKWATER study, standard chemotherapy encorafenib + cetuximab They tested the addition of targeted drugs called [name of drug].
The risk of death was reduced by approximately half; the rate at which the tumor shrank also increased significantly.
Knowing the gene alterations in a patient's tumor allows for the selection of personalized and much more effective treatments. This, “"Personalized cancer treatment"” It is a fine example of understanding.
Colon Cancer Next-generation targeted therapy for HER2-positive patients
In the HORIZON-CRC01 study, HER2 in patients who carry this protein and do not respond to standard treatments trastuzumab rezetekan This antibody-drug combination significantly delayed disease progression compared to standard treatment.
Targeted therapies deliver chemotherapy directly into cancer cells, causing less damage to healthy tissues. Drugs in this class are proving effective against an increasing number of cancer types.
Lung Cancer – reduced the risk of postoperative recurrence.
Some types of lung cancer REJECTION It carries a gene mutation called [name]. In the study LIBRETTO-432, to these patients who have undergone surgery selperkatinib Administering this pill reduces the risk of cancer returning or death. ratio reduced.
Using targeted medication along with surgery in the early stages can significantly prevent cancer recurrence. Furthermore, new and effective pill options have been developed for lung cancer patients carrying rare genetic mutations.
Breast Cancer — New combination for patients carrying the PIK3CA gene alteration.
Victoria-1 study, hormone positive / HER2 negative and PIK3CA in breast cancer patients carrying the genetic alteration and who have shown progression in previous treatment gedatolisib They evaluated combining a new drug called [drug name] with hormone therapy and obtained promising results.
Additionally, a new targeted therapy drug for triple-negative breast cancer has been reported to both slow disease progression and extend survival.
Breast cancer is not a single disease; treatments are increasingly being selected with greater precision for different subtypes, and the options are expanding.
Immunotherapy — Treatments that utilize the body's own defenses are expanding.
Immunotherapy is a treatment approach that strengthens the body's immune system to fight cancer. Key developments this year include:
- In advanced melanoma, cell therapy involves multiplying and returning the patient's own immune cells.lifileucelIt has been shown to provide long-term benefits.
- Next-generation targeted immunotherapy drugs are used in head and neck cancers and some other tumors.bispecific treatments) generated promising responses.
- New combinations were tried for some patients who did not respond to immunotherapy.
Immunotherapy treatments are no longer limited to just a few types of cancer; they are reaching more and more patients and can provide very long-term control in some cases.
Supportive Care — Low-cost, simple approaches have also come to the forefront.
This year's meeting focused not only on new drugs, but also on simple and low-cost methods that improve patients' quality of life before chemotherapy. dietary regulations And yoga Data was shared indicating that movement-based activities like these are beneficial to patients. Additionally, some medications used in the treatment of diabetes and weight loss (GLP-1 groupThe potential benefits for cancer patients were discussed.
Good cancer care is not just about treating the tumor, but also about making the patient feel good. Sometimes the most valuable improvements come through the simplest methods.
Key Points to Remember
- Cancer treatment is advancing rapidly — new and more effective options emerge each year for many types of cancer.
- Personalized treatment is becoming increasingly important; knowing the genetic characteristics of the tumor allows for the selection of the most appropriate medication.
- “Smart drugs” and targeted therapies can deliver better results with fewer side effects compared to conventional chemotherapy.
- Immunotherapeutic therapies are reaching more patients.
- Quality of life stands out as an integral part of the treatment.
Important Note: This article is for general informational purposes only and does not constitute personal medical advice. Some of the treatments mentioned here are still under investigation or may not be suitable in all countries/for all patients. Each patient's situation is unique. Decisions regarding your treatment should only be made in consultation with your attending physician.
Preparer: Tansan Clinic • June 2026
